| TIBOTEC PHARMACEUTICALS LTD. Patent applications |
| Patent application number | Title | Published |
|---|
| 20110165093 | MICROBICIDAL PYRIMIDINE OR TRIAZINE FOR PREVENTING SEXUAL HIV TRANSMISSION - The present invention concerns the microbicidal activity of certain pyrimidine or triazine containing non-nucleoside reverse transcriptase inhibitors. The compounds of the present invention inhibit the systemic infection of a human being with HIV, in particular, the present compounds prevent sexual HIV transmission in humans. | 07-07-2011 |
| 20100234375 | HIV INHIBITING 5-(HYDROXYMETHYLENE AND AMINOMETHYLENE) SUBSTITUTED PYRIMIDINES - This invention concerns 5-(hydroxymethylene and aminomethylene)pyrimidine derivatives having HIV (Human Immunodeficiency Virus) replication inhibiting properties, to the preparation thereof and to pharmaceutical compositions comprising these compounds. | 09-16-2010 |
| 20100173381 | CRYSTAL STRUCTURES OF HIV-1 PROTEASE INHIBITORS BOUND TO HIV-1 PROTEASE - Described herein are methods for rational design of inhibitors of HIV-1 protease, and crystal structures of HIV-1 protease inhibitors bound to HIV-1 protease. | 07-08-2010 |
| 20100173282 | MUTATIONAL PROFILE IN HIV-1 GAG CLEAVAGE SITE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE - The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e. correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management. | 07-08-2010 |
| 20100120795 | POWDERS FOR RECONSTITUTION - This invention relates to powders for reconstitution comprising the NNRTI TMC278 dispersed in certain water-soluble polymers, which can be used in the treatment of HIV infection. | 05-13-2010 |
| 20100113440 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS - Compounds of the Formula (I) including a stereoisomer thereof, or an N-oxide, a pharmaceutically acceptable addition salt, or a pharmaceutically acceptable addition solvate thereof; useful as HCV inhibitors; processes for preparing these compounds as well as pharmaceutical compositions comprising these compounds as active ingredient. | 05-06-2010 |
| 20100094028 | METHODS FOR THE PREPARATION OF HEXAHYDROFURO[2,3-b]FURAN-3-OL - Methods for the preparation of hexahydrofuro[2,3-b]furan-3-ol and especially its enantiomer (3R,3aS,6aR) hexahydrofuro[2,3-b]furan-3-ol, as well as certain novel intermediates for use in such methods. | 04-15-2010 |
| 20090197903 | PROCESS FOR PREPARING SPRAY DRIED FORMULATION OF TMC125 - This invention relates to a process for producing a spray-dried powder comprising microcrystalline cellulose in a solid dispersion of the anti-HIV compound etravirine (TMC125) in a water-soluble polymer. | 08-06-2009 |
| 20090156595 | Pteridines useful as HCV inhibitors and methods for the preparation thereof - The present invention relates to the use of pteridines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents. | 06-18-2009 |
| 20090131460 | PYRIDO[2,3-D]PYRIMIDINES USEFUL AS HCV INHIBITORS, AND METHODS FOR THE PREPARATION THEREOF - The present invention relates to the use of pyrido[2,3-d]pyrimidines as inhibitors of HCV replication as well as their use in pharmaceutical compositions aimed to treat or combat HCV infections. In addition, the present invention relates to pyrido-[2,3-d]pyrimidines compounds per se and their use as medicines. The present invention also concerns processes for the preparation of such compounds, pharmaceutical compositions comprising them, and combinations of said compounds with other anti-HCV agents. | 05-21-2009 |
| 20080287488 | Use of a Sulfonamide Compound For Improving the Pharmacokinetics of a Drug - A method for improving the pharmacokinetics of drugs, which are metabolized by cytochrome P450 monooxygenase is disclosed. More specifically it relates to a method for improving the pharmacokinetics of retroviral protease inhibitors and in particular for improving the pharmacokinetics of human immunodeficiency virus (HIV) protease inhibitors. A pharmaceutical composition and its use in the manufacture of a medicament for the inhibition or treatment of an HIV infection or AIDS in a human being are also part of the invention. | 11-20-2008 |
